Document is current
Any future updates will be listed below
-
Authors
Pazan, Farhad
Wehling, Martin
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 14 November 2020
Accepted: 25 February 2021
First Online: 10 March 2021
Declarations
:
: MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire and LEO Pharma. FP declares that he has no conflict of interest.
: Approval from a medical ethics committee was not necessary for this narrative review.
: For this narrative review formal consent is not required.
